MOTS-c Reconstitution Calculator

No. MOTS-c is not presented in the corpus as an approved drug for any indication, and the current literature frames it as an experimental mitochondrial-derived peptide with biomarker and therapeutic potential rather than an established medicine (review, observational, animal). Human data in the corpus are mainly observational biomarker studies in obesity, acute coronary syndromes, atrial fibrillation, thyroid disease, dialysis, and hematologic cancer response monitoring, not interventional efficacy trials.

Most real-world interest centers on fat loss, insulin resistance, exercise-mimetic effects, mitochondrial support, recovery, and cardiometabolic health (practitioner consensus). The strongest corpus support is mechanistic and preclinical: MOTS-c activates AMPK/PGC-1α-linked pathways, improves skeletal muscle mitochondrial bioenergetic efficiency, lowers oxidative stress, and shows protective effects in cardiac, lung, liver, cartilage, brain, and muscle injury models (animal, in-vitro, mechanistic). For body-composition or glucose-control goals, the evidence is indirect: circulating MOTS-c associates with obesity and insulin resistance in humans, but obesity studies do not prove that injecting MOTS-c causes weight loss in people (observational).

There is no standardized human therapeutic dose in the corpus. Preclinical studies commonly use intraperitoneal dosing in the 0.5-20 mg/kg range depending on model: 0.5 mg/kg in ex vivo rat heart ischemia-reperfusion optimization, 5 mg/kg daily for 2 weeks in radiation lung injury (engineered R13A-MOTS-c) and 5 mg/kg in placental/IUGR models, 15 mg/kg twice daily in mouse cachexia, and 20 mg/kg in LPS-sepsis brain injury models (animal). A native MOTS-c lung protection study used 5 mg/kg in a hyperoxia-induced BPD model. Common self-experimentation protocols are much lower on a body-weight basis: 5-15 mg/day subcutaneous, often 5 days on / 2 days off or daily for 2-4 weeks, then reassess (community protocol). At 160 lb/73 kg, that equals about 0.07-0.21 mg/kg/day, far below most animal doses (community protocol). Evidence-based human dose conversion is not established.

Subcutaneous is the default practical route because the corpus therapeutic studies use parenteral administration and show bioactivity after systemic exposure (animal). There is no human oral dosing or pharmacokinetic protocol in the corpus, and engineered variants were developed specifically to improve cellular uptake, implying native MOTS-c has delivery limitations (mechanistic, animal). Oral use is therefore speculative. If the goal is reproducible exposure, SC is the more defensible route (practitioner consensus).

There are no long-term human safety trials in the corpus. Preclinical studies typically run from acute administration to about 2 weeks, with some disease-model dosing extending through the experimental window; this supports short cycles better than chronic indefinite use (animal). Practical use is usually 2-6 week blocks, then 1-4 weeks off, especially when the target is training adaptation, insulin sensitivity, or recovery (community protocol). Continuous long-term daily use has weak evidence.

Most plausible effects are improved training tolerance, slightly better energy handling, reduced fatigue, and possibly better glucose disposal rather than dramatic fat loss by itself (mechanistic, animal, practitioner consensus). In muscle, MOTS-c improves intrinsic mitochondrial function and reduces ROS without clearly increasing mitochondrial content, which fits a “quality/efficiency” effect more than a stimulant effect (animal, mechanistic). Human biomarker studies show MOTS-c is altered in obesity, cardiovascular disease, AF, thyroid autoimmunity, and other metabolic-inflammatory states, but these studies do not establish symptom improvement from treatment (observational). If someone expects semaglutide-like appetite suppression or testosterone-like performance enhancement, the corpus does not support that.

Direct human adverse-event data are sparse. Based on the biology and animal literature, the main concerns are injection-site irritation, headache, nausea, appetite change, lightheadedness, and unexpected shifts in glucose handling or training recovery (mechanistic, animal, practitioner consensus). Because MOTS-c modulates AMPK, redox signaling, inflammation, Nrf2, mitophagy, and apoptosis-related pathways across multiple tissues, it should be treated as a system-active peptide rather than a benign supplement (mechanistic, animal). People on glucose-lowering drugs should monitor glucose more closely (practitioner consensus).

Pregnancy: avoid routine use. The corpus includes a mouse placental/IUGR study showing benefit via Nrf2, but that is not a safety study and cannot justify use in human pregnancy (animal). Breastfeeding data are absent. Cancer: caution. MOTS-c is being discussed as a therapeutic peptide in metabolic disease and tissue protection, but the corpus does not establish cancer safety across tumor types, and mitochondrial stress-signaling peptides can have context-dependent biology (review, mechanistic). If there is active cancer, recent cancer treatment, or pregnancy, default to specialist supervision rather than self-experimentation (practitioner consensus).

The corpus does not provide product-handling specifications. In practice, lyophilized peptide is usually stored refrigerated before and after reconstitution, protected from heat/light, and used within a short refrigerated window after mixing (community protocol). For travel, keep it in the original labeled vial, use a cooled case if reconstituted, and carry bacteriostatic diluent/syringes only where legally and practically appropriate (community protocol). Repeated warm exposure is generally avoided because peptides are prone to degradation (practitioner consensus).